Literature DB >> 31793501

Validation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for Mycobacterium tuberculosis.

Gomathi Sivaramakrishnan1, Balaji Subramanyam1, Michel Prem Kumar1, Radhika Golla1, Srikanth Prasad Tripathy1, Rajesh Mondal1.   

Abstract

Background: Bedaquiline (BDQ) is a new antituberculosis (TB) drug effectively used for the treatment of multidrug-resistant and extensively drug-resistant TB. However, the reports on drug-susceptibility testing (DST) for BDQ are scarce. The study aimed to validate and standardize BDQ DST by BACTEC MGIT 960 system for Mycobacterium tuberculosis.
Methods: A panel of ten M. tuberculosis isolates comprising 8 BDQ sensitive and 2 BDQ resistant strains were used to test accuracy, repeatability, and reproducibility of BDQDST by MGIT 960. BDQ DST by Middlebrook 7H11 agar method using polystyrene tubes was used as a standard method to calculate the accuracy of the validation.
Results: DST by MGIT for BDQ showed 100% accuracy, repeatability, and reproducibility, although variations were observed in the growth units of the "test" MGIT tubes between technologist and drug stocks while testing for reproducibility.
Conclusion: BDQ DST by MGIT 960 system is accurate, repeatable, and reproducible and hence can be implemented in certified laboratories routinely performing DST by MGIT 960 system.

Entities:  

Keywords:  Bedaquiline; MGIT 960; Mycobacterium tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 31793501     DOI: 10.4103/ijmy.ijmy_151_19

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  1 in total

1.  GeneXpert MTB/RIF combined with conventional methods for tuberculosis in Shanghai Regional Medical Center: a retrospective diagnostic study.

Authors:  Huanhuan Zhang; Hong Li; Meiyu Tan; Zhenhao Liu; Jie Gu; Yi Zhang; Huiming Sheng
Journal:  Ann Transl Med       Date:  2022-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.